# The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

> **NCT00483938** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 236 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Pegylated-interferon Alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00483938
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483938, "The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00483938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*